Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16227065 | 1.00 | OPRD1 (0.48) | OPRD1SLC6A9KDM4ECYP1A2CYP3A4 | |
| SCHEMBL7665838 | 0.72 | OPRD1 (0.69) | OPRD1SLC6A9KDM4ECYP1A2CYP3A4 | |
| SCHEMBL9252941 | 0.70 | OPRD1 (0.48) | OPRD1SLC6A9KDM4ECYP1A2CYP3A4 | |
| SCHEMBL13955139 | 0.69 | OPRD1 (0.50) | OPRD1SLC6A9KDM4EOPRL1OPRM1 | |
| SCHEMBL4499828 | 0.68 | SIGMAR1 (0.52) | OPRD1SLC6A9OPRL1OPRM1SIGMAR1 | |
| SCHEMBL16226518 | 0.68 | OPRD1 (0.63) | OPRD1KDM4ECYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14191407 | 0.67 | OPRD1 (0.66) | OPRD1 | |
| SCHEMBL13163119 | 0.66 | OPRM1 (0.51) | OPRD1SLC6A9KDM4EOPRL1OPRM1 | |
| SCHEMBL21787342 | 0.66 | OPRM1 (0.51) | OPRD1SLC6A9KDM4EOPRL1OPRM1 | |
| SCHEMBL17012864 | 0.66 | OPRD1 (0.46) | OPRD1SLC6A9OPRL1OPRM1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | OPRD1 66/4885SLC6A9 4793/4885KDM4E 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.